Medtronic beats Q2 expectations, raises full-year outlook

Go back to Medtronic beats Q2 expectations, raises full-year outlook

Medtronic, Inc. (MDT) PT Raised to $114 at Wells Fargo

November 19, 2025 5:32 AM EST

Wells Fargo analyst Larry Biegelsen raised the price target on Medtronic, Inc. (NYSE: MDT) to $114.00 (from $110.00) while maintaining a Overweight rating.

The analyst comments "FQ2 org growth of 5.5% exceeded Street, while EPS beat even with the increased opex spend. MDT continues to... More

Medtronic, Inc. (MDT) PT Raised to $117 at Citi

November 18, 2025 1:46 PM EST

Citi analyst Joanna Wuensch raised the price target on Medtronic, Inc. (NYSE: MDT) to $117.00 (from $112.00) while maintaining a Buy rating.

... More